Total Payments
$668,061
2024 Payments
$38,619
Companies
25
Transactions
381
Medicare Patients
3,753
Medicare Billing
$285,792
Payment Breakdown by Category
Consulting$440,183 (65.9%)
Research$99,160 (14.8%)
Other$95,938 (14.4%)
Travel$19,092 (2.9%)
Food & Beverage$13,688 (2.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $440,183 | 61 | 65.9% |
| Unspecified | $99,160 | 38 | 14.8% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $44,750 | 10 | 6.7% |
| Grant | $27,000 | 6 | 4.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $22,550 | 8 | 3.4% |
| Travel and Lodging | $19,092 | 55 | 2.9% |
| Food and Beverage | $13,688 | 201 | 2.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,600 | 1 | 0.2% |
| Entertainment | $37.79 | 1 | 0.0% |
Payments by Type
General
$568,901
343 transactions
Research
$99,160
38 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $282,293 | 46 | $0 (2023) |
| Bausch & Lomb, a division of Bausch Health US, LLC | $121,138 | 94 | $0 (2021) |
| Novartis Pharma AG | $59,014 | 5 | $0 (2020) |
| Bausch & Lomb Americas Inc. | $54,508 | 75 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $38,820 | 33 | $0 (2024) |
| Carl Zeiss Meditec, Inc. | $21,420 | 21 | $0 (2023) |
| EyePoint Pharmaceuticals US, Inc. | $17,042 | 20 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $10,971 | 1 | $0 (2018) |
| Merck Sharp & Dohme LLC | $9,512 | 9 | $0 (2024) |
| SANOFI US SERVICES INC. | $7,950 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $38,619 | 35 | Bausch & Lomb Americas Inc. ($19,849) |
| 2023 | $38,665 | 59 | Bausch & Lomb Americas Inc. ($17,329) |
| 2022 | $40,409 | 59 | Bausch & Lomb Americas Inc. ($17,330) |
| 2021 | $56,152 | 48 | Bausch & Lomb, a division of Bausch Health US, LLC ($27,576) |
| 2020 | $260,481 | 46 | Novartis Pharmaceuticals Corporation ($150,792) |
| 2019 | $139,873 | 53 | Novartis Pharmaceuticals Corporation ($109,621) |
| 2018 | $64,708 | 45 | Bausch & Lomb, a division of Bausch Health US, LLC ($45,114) |
| 2017 | $29,153 | 36 | Regeneron Pharmaceuticals, Inc. ($16,738) |
All Payment Transactions
381 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Bausch & Lomb Americas Inc. | Stellaris (Device) | Food and Beverage | In-kind items and services | $21.65 | General |
| Category: Ophthalmology | ||||||
| 11/06/2024 | Bausch & Lomb Americas Inc. | Stellaris (Device) | Food and Beverage | In-kind items and services | $111.90 | General |
| Category: Ophthalmology | ||||||
| 10/23/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $7,755.00 | General |
| 10/23/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 10/19/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: Ophthalmology | ||||||
| 10/19/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $77.04 | General |
| Category: Ophthalmology | ||||||
| 10/09/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $65.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/09/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $60.02 | General |
| Category: IMMUNOLOGY | ||||||
| 10/09/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $55.01 | General |
| Category: IMMUNOLOGY | ||||||
| 10/08/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $931.25 | General |
| Category: IMMUNOLOGY | ||||||
| 10/08/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $345.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/08/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $75.40 | General |
| Category: IMMUNOLOGY | ||||||
| 10/08/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $75.40 | General |
| Category: IMMUNOLOGY | ||||||
| 09/18/2024 | Bausch & Lomb Americas Inc. | Stellaris (Device) | Food and Beverage | In-kind items and services | $60.13 | General |
| Category: Ophthalmology | ||||||
| 08/05/2024 | Bausch & Lomb Americas Inc. | XIIDRA (Drug), MIEBO | Food and Beverage | In-kind items and services | $161.38 | General |
| Category: Ophthalmology | ||||||
| 07/31/2024 | Bausch & Lomb Americas Inc. | Stellaris (Device) | Food and Beverage | In-kind items and services | $96.99 | General |
| Category: Ophthalmology | ||||||
| 07/18/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological), EYLEA HD | Food and Beverage | In-kind items and services | $66.65 | General |
| Category: OPHTHALMOLOGY | ||||||
| 07/12/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $2,820.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 07/12/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $1,880.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,146.92 | Research |
| Study: Longitudinal Quantitative Anterior Chamber Cell Analysis Following Vamikibart Intravitreal Therapy in Patients With Uveitic Macular Edema From the DOVETAIL Clinical Trial | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $994.00 | Research |
| Study: Volumetric Fluid Dynamics Using Machine-Learning Augmented Analysis in Patients With Uveitic Macular Edema Receiving Vamikibart in the DOVETAIL Study | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $994.00 | Research |
| Study: Longitudinal Quantitative Ultra-Widefield Fluorescein Angiography Leakage Dynamics in Patients With Uveitic Macular Edema Following Intravitreal Anti?IL-6 Therapy With Vamikibart | ||||||
| 06/25/2024 | EyePoint Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $33.95 | General |
| 05/17/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $122.40 | General |
| Category: OPHTHALMOLOGY | ||||||
| 05/16/2024 | Ocular Therapeutix, Inc. | DEXTENZA (Drug) | Food and Beverage | In-kind items and services | $78.49 | General |
| Category: Corticosteroid intracanalicular insert | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CRTH258B2301, CRTH258B2302, CRTH258C2301, CRTH258C2302, CRTH258AUS04 | Novartis Pharma AG | $49,500 | 2 |
| Publication support research related | Novartis Pharma AG | $9,514 | 3 |
| CRTH258A2301 | Novartis Pharmaceuticals Corporation | $7,228 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $6,188 | 7 |
| A TWO YEAR RANDOMIZED DOUBLE MASKED MULTICENTER THREE ARM STUDY COMPARING THE SAFETY AND EFFICACY OF RTH258 VERSUS AFLIBERCEPT IN SUBJECTS WITH NEOVASCULAR AGE RELATED MACULAR DEGENERATIONGE RELATED MACULAR DEGENERATION | Novartis Pharmaceuticals Corporation | $3,112 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH BEOVU RESEARCH | Novartis Pharmaceuticals Corporation | $3,007 | 1 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE-MASKED, MULTICENTER, TWO-ARM STUDY COMPARING THE EFFICACY AND SAFETY OF ESBA1008 VERSUS EYLEA IN SUBJECTS WITH EXUDATIVE AGE RELATED MACULAR DEGENERATION | Novartis Pharmaceuticals Corporation | $2,182 | 1 |
| BRO-MS-95789 LONGITUDINAL ASSESSMENT OF ELLIPSOID ZONE SUBRETINAL HYPERREFLECTIVE MATERIAL & SUB-RPE DISEASE FEATURES IN NEOVASCULAR AMD IN THE OSPREY | NOVARTIS PHARMACEUTICALS CORPORATION | $2,045 | 1 |
| CLR-3726/BRO-MS -98408 THE IMPACT OF FLUID VOLATILITY ON SUBRETINAL HYPERREFLECTIVE MATERIAL AND ELLIPSOID ZONE INTEGRITY IN NAMD IN THE OSPREY STUDY | NOVARTIS PHARMACEUTICALS CORPORATION | $2,045 | 1 |
| BRO-MS -98072 LONGITUDINAL HIGHER-ORDER OCT ASSESSMENT OF QUANTITATIVE FLUID DYNAMICS AND THE TOTAL RETINAL FLUID INDEX IN NEOVASCULAR AMD | NOVARTIS PHARMACEUTICALS CORPORATION | $1,875 | 1 |
| BRO-MS-95913 LONGITUDINAL HIGHER-ORDER OCT ASSESSMENT OF MACULAR FLUID DYNAMICS AND RETINAL FLUID INDEX IN NEOVASCULAR AMD FROM THE OSPREY STUDY | NOVARTIS PHARMACEUTICALS CORPORATION | $1,875 | 1 |
| A DOUBLE- MASKED, RANDOMIZED, ACTIVE-CONTROLLED, PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL ADMINISTRATION OF VEGF TRAP-EYE IN PATIENTS WITH DIABETIC MACULAR EDEMA | Regeneron Pharmaceuticals, Inc. | $1,315 | 5 |
| BRO-OP -92977 LONGITUDINAL DYNAMICS IN OUTER RETINAL INTEGRITY IN NAMD: HIGHER-ORDER OCT FEATURE EXTRACTION AND INSIGHTS FROM THE OSPREY TRIAL | NOVARTIS PHARMACEUTICALS CORPORATION | $1,200 | 1 |
| Longitudinal Quantitative Anterior Chamber Cell Analysis Following Vamikibart Intravitreal Therapy in Patients With Uveitic Macular Edema From the DOVETAIL Clinical Trial | F. Hoffmann-La Roche AG | $1,147 | 1 |
| BRO-OP -99111 FLUID COMPARTMENT VOLATILITY AND DYNAMICS IN NEOVASCULAR AMD TREATED WITH ANTI-VEGF THERAPY: IMPLICATIONS FOR OUTER RETINAL INTEGRITY | NOVARTIS PHARMACEUTICALS CORPORATION | $1,000 | 1 |
| Longitudinal Quantitative Ultra-Widefield Fluorescein Angiography Leakage Dynamics in Patients With Uveitic Macular Edema Following Intravitreal Anti?IL-6 Therapy With Vamikibart | F. Hoffmann-La Roche AG | $994.00 | 1 |
| Volumetric Fluid Dynamics Using Machine-Learning Augmented Analysis in Patients With Uveitic Macular Edema Receiving Vamikibart in the DOVETAIL Study | F. Hoffmann-La Roche AG | $994.00 | 1 |
| BRO-OP -98871 FLLUID BURDEN AND OUTER RETINAL INTEGRITY DYNAMICS IN NAMD: HIGHER-ORDER OCT ASSESSMENTS FROM THE OSPREY TRIAL | NOVARTIS PHARMACEUTICALS CORPORATION | $750.00 | 1 |
| BRO-PO -93997 CHANGES IN SUB-RETINAL PIGMENT EPITHELIUM VOLUME IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH TREATMENT: OSPREY TRIAL DATA SET | NOVARTIS PHARMACEUTICALS CORPORATION | $750.00 | 1 |
| BRO-OP-93996 RETINAL FLUID INDEX, A NOVEL OPTICAL COHERENCE TOMOGRAPHY PARAMETER IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: OSPREY TRIAL DATA | NOVARTIS PHARMACEUTICALS CORPORATION | $600.00 | 1 |
| Cleveland Clinic DOVETAIL UME advanced retinal fluid analysis | F. Hoffmann-La Roche AG | $475.36 | 1 |
| Cleveland Clinic DOVETAIL UME vascular leakage analysis | F. Hoffmann-La Roche AG | $475.36 | 1 |
| BRO-AB-97968 FLUID COMPARTMENT VOLATILITY AND DYNAMICS IN NEOVASCULAR AMD TREATED WITH ANTI-VEGF THERAPY: IMPLICATIONS FOR OUTER RETINAL INTEGRITY | NOVARTIS PHARMACEUTICALS CORPORATION | $475.00 | 1 |
| BRO-AB -93999 FLUID BURDEN AND OUTER RETINAL INTEGRITY DYNAMICS IN NAMD: HIGHER-ORDER OCT ASSESSMENTS FROM THE OSPREY TRIAL | NOVARTIS PHARMACEUTICALS CORPORATION | $356.00 | 1 |
| A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients With Diabetic Macular Edema | Regeneron Pharmaceuticals, Inc. | $56.70 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 917 | 1,664 | $522,523 | $66,901 |
| 2022 | 12 | 1,020 | 1,817 | $549,460 | $80,123 |
| 2021 | 9 | 899 | 1,632 | $414,672 | $64,564 |
| 2020 | 12 | 917 | 1,536 | $554,194 | $74,205 |
Total Patients
3,753
Total Services
6,649
Medicare Billing
$285,792
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 197 | 350 | $143,166 | $22,452 | 15.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 182 | 296 | $53,291 | $13,897 | 26.1% |
| 67028 | Injection of drug into eye | Facility | 2023 | 64 | 184 | $180,323 | $12,506 | 6.9% |
| 92134 | Imaging of retina | Facility | 2023 | 323 | 651 | $94,635 | $11,212 | 11.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 24 | 24 | $14,472 | $2,386 | 16.5% |
| 92014 | Established patient complete exam of visual system | Facility | 2023 | 31 | 34 | $10,588 | $1,908 | 18.0% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Facility | 2023 | 42 | 52 | $14,300 | $1,544 | 10.8% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Facility | 2023 | 18 | 22 | $7,019 | $509.49 | 7.3% |
| 92250 | Photography of the retina | Facility | 2023 | 24 | 28 | $3,510 | $432.00 | 12.3% |
| 92285 | Photography of content of eyes | Facility | 2023 | 12 | 23 | $1,219 | $53.59 | 4.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 217 | 320 | $117,550 | $22,343 | 19.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 233 | 408 | $74,832 | $18,437 | 24.6% |
| 67028 | Injection of drug into eye | Facility | 2022 | 61 | 175 | $152,219 | $12,293 | 8.1% |
| 92134 | Imaging of retina | Facility | 2022 | 320 | 685 | $91,733 | $12,062 | 13.1% |
| 67036 | Removal of eye fluid (vitreous) between lens and retina | Facility | 2022 | 11 | 11 | $48,763 | $6,800 | 13.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 32 | 32 | $17,232 | $2,956 | 17.2% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Facility | 2022 | 54 | 68 | $17,000 | $1,933 | 11.4% |
| 92014 | Established patient complete exam of visual system | Facility | 2022 | 14 | 20 | $4,060 | $1,124 | 27.7% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Facility | 2022 | 23 | 31 | $10,503 | $895.40 | 8.5% |
| 92242 | Exam of retinal blood vessels and blood vessels between the white part of eye and retina using a special camera after injection of a dye | Facility | 2022 | 20 | 21 | $11,361 | $873.67 | 7.7% |
| 92250 | Photography of the retina | Facility | 2022 | 22 | 25 | $3,199 | $356.87 | 11.2% |
| 92285 | Photography of content of eyes | Facility | 2022 | 13 | 21 | $1,008 | $48.37 | 4.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 261 | 523 | $99,058 | $25,144 | 25.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 140 | 167 | $60,476 | $11,337 | 18.7% |
| 92134 | Diagnostic imaging of retina | Facility | 2021 | 293 | 631 | $86,148 | $11,201 | 13.0% |
About Dr. Sunil Srivastava, MD
Dr. Sunil Srivastava, MD is a Ophthalmology healthcare provider based in Cleveland, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1225094378.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sunil Srivastava, MD has received a total of $668,061 in payments from pharmaceutical and medical device companies, with $38,619 received in 2024. These payments were reported across 381 transactions from 25 companies. The most common payment nature is "Consulting Fee" ($440,183).
As a Medicare-enrolled provider, Srivastava has provided services to 3,753 Medicare beneficiaries, totaling 6,649 services with total Medicare billing of $285,792. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Cleveland, OH
- Active Since 04/25/2006
- Last Updated 11/07/2011
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1225094378
Products in Payments
- BEOVU (Drug) $163,665
- STELLARIS (Device) $58,307
- RTH258C_BEOVU_OPHTHALMOLOGY (Drug) $49,500
- Stellaris (Device) $22,318
- KEVZARA SARILUMAB INJECTION (Biological) $16,738
- YUTIQ (Drug) $16,642
- VISUDYNE (Drug) $15,714
- EYLEA (Biological) $14,277
- STELLARIS ELITE (Device) $13,135
- SAR422459 (Drug) $10,971
- STELLARIS PC (Device) $10,677
- BLZ_BEOVU_OPHTHALMOLOGY (Drug) $9,514
- CIRRUS HD-OCT (Device) $8,750
- RETISERT (Drug) $7,204
- Humira (Biological) $6,091
- CLARUS 500 (Device) $5,500
- EYLEA HD (Biological) $4,990
- Lucentis (Biological) $4,835
- XIPERE (Drug) $3,970
- CIRRUS 6000 with AngioPlex (Device) $3,850
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Cleveland
Peter Kaiser, Md, MD
Ophthalmology — Payments: $1.7M
Ophthalmology $1.7M
Dr. Justis Ehlers, M.d, M.D
Ophthalmology — Payments: $818,485
Ophthalmology $818,485
William Wiley, M.d, M.D
Ophthalmology — Payments: $775,102
Ophthalmology $775,102
Yasha Modi, M.d, M.D
Ophthalmology — Payments: $244,095
Ophthalmology $244,095
Dr. Douglas Rhee, M.d, M.D
Ophthalmology — Payments: $162,043
Ophthalmology $162,043
Faruk Orge, Md, MD
Ophthalmology — Payments: $156,811
Ophthalmology $156,811